Home › NCT06389721
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion criteria: Objective 1 Inclusion criteria 1. Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements. 2. ECOG Performance Status of 0-2; 3. Willing to come to MD Anderson for the imaging sessions. 4. Are 18 years of age or above. 5. Have a diagnosis of breast cancer. 6. will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel; Objective 2 Inclusion criteria: 1\) Inclusion criteria: Identical to Objective 1 and are willing to participate in the therapy sessions at their homes. Exclusion Criteria Objective 1 Exclusion criteria: 1. Participants who are taking any antipsychotic medications. 2. With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy. 3. Have ever been diagnosed with bipolar disorder or schizophrenia. 4. Known, previously diagnosed peripheral neuropathy from any causes and 5. A history of head injury or who have known seizure activity. Objective 2 Exclusion criteria 1\) Same exclusion criteria as in Objective1. Medication usage will be tracked for patients in all groups. Once prescribed, participants must remain on a stable course of medications throughout the course of chemotherapy.
About the study
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN).
Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.
What is being tested
- Electroencephalogram (EEG) (diagnostic test)
Sponsor: M.D. Anderson Cancer Center · Participants: 45 · Started: Jul 16, 2024
Contact the study team
- Lorenzo Cohen, PHD · Phone: (713) 745-4260
Official record on ClinicalTrials.gov — NCT06389721
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.